Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
Zeta Surgical and HOPE Therapeutics have treated the first patient using the FDA-cleared Zeta TMS Navigation System, which applies AI and computer vision to guide transcranial magnetic stimulation therapy with high precision.
Attunio Health has introduced a precision psychiatry platform that combines AI, biomarker testing, and wearable monitoring to personalize mental health treatment and provide continuous clinical feedback.
The Advanced Research Projects Agency for Health awarded up to $39.3 million to Children's Hospital of Philadelphia and collaborators to create a wearable system that uses AI to detect low fetal oxygen during labor.
Insilico Medicine and SK Biopharmaceuticals have entered a research and development collaboration worth up to $2.5 billion to develop drug candidates for neuroimmune disorders using Insilico’s AI platform.
ChemT Biotechnology has raised $4 million in seed funding led by Wavemaker Ventures, with participation from SEEDS and other investors, to expand its AI and experimental infrastructure for biomanufacturing.
Tredence has acquired KMK Consulting, a New Jersey-based analytics and consulting firm serving major pharmaceutical companies, to accelerate growth in healthcare and life sciences. The company expects the sector to contribute 25% of its revenue by 2028.
Brenig Therapeutics will present new data on its AI designed brain-penetrant NLRP3 inhibitor BT-409 at the Keystone Symposia on Neuroinflammation in Health and Disease, showcasing how its Hybrid AI Platform supports CNS drug discovery.
DropGenie has closed a Seed+ financing round led by Skeleton Key with participation from Merck Global Health Innovation Fund and CQDM to support the commercial launch of its first gene editing product.
ChartSpan has completed the acquisition of Validic, integrating Validic’s health data technology with ChartSpan’s care management services to create a unified platform for continuous patient monitoring and proactive clinical care.
A paper in Alzheimer's & Dementia highlights SpeechDx's role in developing AI tools that use speech patterns to detect early cognitive decline and support personalized Alzheimer's care.
AnHorn Medicines announced that its neuroprotective candidate AH-008 has received U.S. FDA IND clearance and Taiwan CDE Index Case designation, enabling the company to begin clinical trials for preventing chemotherapy-induced peripheral neuropathy.
Co-Diagnostics hosted a delegation from its Saudi joint venture CoMira Diagnostics in Salt Lake City for the unveiling of a future automated PCR test kit manufacturing line, part of a planned technology transfer to Saudi Arabia.
Boltz has announced a collaboration with Takeda to provide its biomolecular AI models and platform across Takeda's research organization, supporting structure prediction, affinity estimation, and molecular design.
XEOS announced the publication of the multicenter BrIMA study in JAMA Surgery, showing that its AURA 10 specimen PET-CT system significantly improved intraoperative margin assessment in breast-conserving surgery.
Arbital Health has introduced ATLAS, a new actuarial modeling tool to help Accountable Care Organizations evaluate provider networks and financial performance under the Centers for Medicare & Medicaid Services' new LEAD Model.
Channel Robotics has raised $4.6 million, including a $2.5 million Seed+ round led by True Ventures, to develop its handheld AI-enabled endoscopic robotic platform and prepare for FDA submission in 2027.
Workera announced that a global medical device manufacturer achieved a 42% average proficiency gain in 13 days using its skills data platform, reaching best-in-class learning velocity and uncovering hidden workforce capabilities.
Vali Health has emerged from stealth with $6 million in funding to develop responsible AI infrastructure for home care agencies, aiming to automate workforce coordination and improve continuity of care.
Lunai Bioworks has secured its first revenue-generating defense contract with the U.S. government through BioSymetrics, formed a national research consortium, and initiated legal proceedings over alleged market manipulation.
LG AI Research has signed a master agreement with D&D Pharmatech to jointly develop oral peptide therapeutics using artificial intelligence, aiming to accelerate drug discovery and improve treatment safety and absorption.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
